SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Valiant Laboratories - Quaterly Results

14 May 2024 Evaluate
The sales for the March 2024 quarter moved down -65.99% to Rs. 305.83 millions as compared to Rs. 899.19 millions during the year ago period.The Net Loss for the quarter ended March 2024 is Rs. -12.18 millions as compared to Net Profit of Rs. 78.28 millions of corresponding quarter ended March 2023Operating profit Margin for the quarter ended March 2024 slipped to -20.27% as compared to 103.36% of corresponding quarter ended March 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 305.83 899.19 -65.99 1820.52 3339.10 -45.48 1820.52 3339.10 -45.48
Other Income 25.03 17.22 45.35 96.82 48.63 99.10 96.82 48.63 99.10
PBIDT -20.27 103.36 -119.61 12.73 399.54 -96.81 12.73 399.54 -96.81
Interest 0.21 0.27 -22.22 0.78 2.54 -69.29 0.78 2.54 -69.29
PBDT -20.48 103.09 -119.87 11.95 397.00 -96.99 11.95 397.00 -96.99
Depreciation 5.02 4.40 14.09 19.48 15.63 24.63 19.48 15.63 24.63
PBT -25.50 98.69 -125.84 -7.53 381.37 -101.97 -7.53 381.37 -101.97
TAX -13.32 20.41 -165.26 -10.93 91.38 -111.96 -10.93 91.38 -111.96
Deferred Tax 2.46 -1.89 -230.16 -1.11 3.38 -132.84 -1.11 3.38 -132.84
PAT -12.18 78.28 -115.56 3.40 289.99 -98.83 3.40 289.99 -98.83
Equity 434.50 325.60 33.45 434.50 325.60 33.45 434.50 325.60 33.45
PBIDTM(%) -6.63 11.49 -157.66 0.70 11.97 -94.16 0.70 11.97 -94.16

Valiant Laboratories Share Price

67.00 0.30 (0.45%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×